top of page
Fond ecrant.jpg

A new test to help detect and monitor cancers

​«We are bringing a new diagnostic solution to improve cancer detection and management throughout the patient care pathway.» 

A simple and accessible test

Our R&D team found that hPG80 protein was present at high levels in the blood of patients with 16 different types of cancer, regardless of the stage of the disease.​

 ​

Building on this groundbreaking French research, we developed a practical and cost-effective blood test: DxPG80.Lab.

DxPG80.Lab: a new device to lead the fight against cancer

Visuel-kit CE IVD.V2.png

Through a simple blood test, the DxPG80.Lab test detects the presence of hPG80, a biomarker associated with cancer activity. 

Commercialized with CE marking​

PICTO CE.png

Easy

Rapid execution

(<3 hours)

Reliability

Affordable

CE-marked

hPG80 is detected in all cancers tested, including those for which no markers are available.

Tested on > 4,000 cancer patients and 1,200 healthy subjects​.

Detected across all stages of 16 different types of cancer​.

Proposing a more efficient support

iStock-Doc analyse data - Light v2.jpg

A biomarker to support decision-making throughout the patient care pathway.​​​​​​​

DxPG80.Lab provides valuable insights to help clinicians optimise patient care.

timeline indications v2.png

DETECTION

DIAGNOSIS

PROGNOSIS

TREATMENT
OUTCOME
PREDICTION

TREATMENT

MONITORING/
FOLLOW-UP

Despite significant progress over the last decade, the burden of cancer continues to rise.

20 million

new cases per year,

expected to rise to 31M in 2040.

> 50% late diagnosis

Over half of cancers in the US are diagnosed at stages III and IV​.

79% vs 11%

79% vs 11% mortality

5-year cancer​ specific mortality when diagnosed late vs early stage​.

couloir hopital_edited.png

Sources: WHO and Cancer Atlas

Strong unmet medical need

To detect cancer earlier and monitor treatment

with a low-cost blood test.

shutterstock_medecin et patient light.jpg

It's time to take concrete action

bottom of page